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TIIVISTELMÄ 
 
Tutkimuksemme tarkoituksena oli tutkia ajallisia ja alueellisia muutoksia MS-taudin ilmaantuvuudessa 
Länsi-Suomessa vuosina 1981-2010. Mukana on yksi maailman korkeimman riskin alueista. 
Kiinnitimme huomiota erityisesti sukupuolten välisiin eroihin ilmaantuvuudessa. 
 
Aineisto kerättiin Pirkanmaan, Etelä-Pohjanmaan ja Vaasan sairaanhoitopiirien 
potilastietojärjestelmistä (kerääjinä M. Holmberg, A. Murtonen ja M-L Sumelahti). Mukaan otettiin 
potilaat, joilla MS-taudin Poserin kriteerit täyttyivät vuosien 1981-2010 välillä.  
 
Ilmaantuvuus laskettiin eri ryhmille alueen, vuosikymmenen, sukupuolen ja iän mukaan. Eroja 
tarkasteltiin myös standardisoitua ilmaantuvuussuhdetta (SIR) hyväksi käyttäen, missä Pirkanmaan 
väestö oli standardiväestö. Miesten ja naisten välisiä ilmaantuvuussuhteita vertailtiin F/M-suhdetta 
(female-to-male-ratio) apuna käyttäen.  
 
Tapausten kokonaismäärä oli 1 617. Ilmaantuvuus kasvoi kaikilla alueilla. Vuosina 2001-2010 
ilmaantuvuus oli Etelä-Pohjanmaalla 14,7/10
5
 henkilövuotta (95% luottamusväli 12,7-16,7), Vaasassa 
11,7 (9,8-13,6) ja Pirkanmaalla 8,2 (7,3-9,1). Etelä-Pohjanmaalla MS-taudin riski oli 1,9 (1,7-2,0) ja 
Vaasassa 1,3 (1,1-1,4) -kertainen verrattuna Pirkanmaahan. Naisten osuus verrattuna miehiin (F/M) 
kasvoi 1,8:sta Etelä-Pohjanmaalla 2,5:een ja Vaasassa 2,9:ään. Pirkanmaalla osuus pysyi ennallaan. 
Diagnostisen viiveen mediaani pieneni tutkimusjakson aikana neljästä vuodesta kahteen vuoteen. 
 
Ilmaantuvuuden kasvu oli merkitsevää erityisesti korkean riskin alueilla (Etelä-Pohjanmaa ja Vaasa) 
naisilla. Kasvua voivat selittää sekä geneettiset että ympäristötekijät. 
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ABSTRACT 
 
Background: MS incidence has increased among females, suggesting the presence of environmental factor 
effects. 
 
Object: Gender-specific MS incidence was studied in medium- and high-risk districts in Finland. 
 
Methods: Cases recruited from Jan 1, 1981 to Dec 31, 2010 in Pirkanmaa (medium-risk), Seinäjoki 
(highrisk) and Vaasa districts were included in this study. The standardized incidence rate (SIR) with 95% 
confidence interval (CI), female-to-male ratios (F/M), and incidences per 105 person years with 95% CIs in 
10-year intervals were determined. 
 
Results: In this study, 1617 cases were included. Compared to Pirkanmaa, the MS risk was 1.9-fold (95% 
CI: 1.7-2.0) greater in Seinäjoki and 1.2-fold (95% CI: 1.1-1.4) greater in Vaasa. Moreover, the risk was 
significantly increased for both males and females. The incidence trends stabilized in Seinäjoki and Vaasa, 
accompanied by an increase in the F/M ratio, while a steady increase in the incidence of MS in Pirkanmaa 
was accompanied by a high F/M ratio. 
 
Conclusion: A high female preponderance accompanied a general increase in incidence since the 1990’s, 
suggesting the influence of environmental factors. In high-risk districts, increased risk prevailed in both 
genders. However, high risk in general reflects both genetic and environmental effects. These effects may 
be shared among other autoimmune diseases, such as type 1 diabetes mellitus, the incidence of which 
follows MS in Finland. Population-based case-control studies are needed to identify these factor effects. 
 
INTRODUCTION 
 
MS incidence has increased, particularly among females [1,2,3,4], indicating the influence of environmental 
factors. The integration of magnetic resonance imaging (MRI) in diagnostic criteria since the 1990’s and 
progress in immunomodulatory drug treatments have contributed to these increasing rates [5,6].  
 
Epidemiologically, MS is characterized by an uneven geographical distribution [7]. Studies performed since 
1964 confirm this observation in Finland [8,9,10], which is located in Northern Europe between the 
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latitudes 60 and70° N. High-risk areas in the western districts, Seinäjoki and Vaasa, are characterized by an 
irregular incidence pattern, and an increased male risk was observed in Seinäjoki in 1979-1993 [10]. 
 
We aimed to analyze the gender-specific incidence in high- and medium-risk areas in 1981-2010 to make 
inferences on the etiological factors correlated with high-risk groups. The incidence in the former 
mediumrisk area Pirkanmaa [8] is studied for the first time. Incidence is regarded as the most important 
indicator of disease frequency, and changes in incidence reflect environmental factors in genetically stable 
populations. 
 
MATERIALS AND METHODS 
 
The districts examined in this study are shown in Figure 1. The total population in 2010 was 850 630 [11]. 
Pirkanmaa Central Hospital (population 485 911) is one of five University hospitals in Finland. Seinäjoki 
and Vaasa Central Hospitals serve populations of 198 469 and 166 250, respectively [11]. Both Seinäjoki 
and Vaasa are mainly rural districts, while Pirkanmaa is more urbanized, which is reflected in the age-
structure and -distribution of its populations. 
 
From 1981 to 2010, the population increased by 19% in Pirkanmaa and 9% in Vaasa, while a 2% decrease 
was reported in Seinäjoki. A 21% decrease in the age group 0-39 years was observed in Seinäjoki and 
Vaasa [11].  
 
Neurological services were evenly distributed between the district hospitals. MS is diagnosed by 
neurologists in central or university hospitals in Finland. [10]. CSF is a routine examination in MS 
diagnostics. MRI scans have been used in diagnostics from 1990 in Pirkanmaa and 1993 in Seinäjoki and 
Vaasa. 
 
The National Institute for Health and Welfare and the local ethical standards committee approved the 
retrospective examination of identified patient records in the hospitals in this study. 
 
Patients with multiple sclerosis in the health care districts of Pirkanmaa, Seinäjoki and Vaasa, including 
Jacobstad, were recruited from hospital registries from January 1, 1981 to December 31, 2010 according to 
multiple sclerosis or morbus demyelinans diagnoses and optic- or retrobulbar neuritis (340, 341 and 377 in 
the International Classification of Diseases, ICD versions 8 and 9, G35, G37 and H46 in ICD-10). The 
patient records were then examined by the authors (MH, AM, M-LS). Patient information was collected on 
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the date, and the quality of the first symptoms and clinical findings were recorded. Confirmatory positive 
results at the time of diagnosis were obtained from patient records for MRI, cerebrospinal fluid (CSF) and 
evoked potentials (EP). The dates of the follow-up MRI results were also recorded. Patient cases were 
included in the analyses when fulfilling the criteria of clinically (CD) or laboratory supported definite 
(LSD) MS as previously described by Poser [12] during January 1, 1981 to December 31, 2010, and when 
the patients resided in the study districts at the year of diagnosis. The patient’s residence was updated using 
a personalized identification number and the year of diagnosis at Statistics Finland. 
 
The age-adjusted and gender-specific incidence per 105 person-years was calculated from January 1, 1981 to 
December 31, 2010 for three 10-year periods (1981-1990, 1991-2000, 2001-2010) with a 95% confidence 
interval (CI) by district. The incidence of the 5-year periods did not change our overall conclusions (data 
not shown). Furthermore, to avoid chance variation, we used 10-year periods in our calculations. Due to the  
small number of cases in the age-specific strata, indirect standardization [13] was used to study regional risk 
during 1981-2010. In this study, the standard population used was the Pirkanmaa population. The incidence 
rates in Pirkanmaa from 1981 to 2010 in each 10-year age group were used to calculate the expected 
numbers of cases for both the Seinäjoki and Vaasa populations. The resulting expected number of cases was 
then compared to the actual observed numbers of cases in Seinäjoki and Vaasa, resulting in the standardized 
incidence rate (SIR), which was the ratio of observed and expected cases. The total and gender-specific 
SIRs with a 95% CI are presented. 
  
RESULTS 
 
The patient characteristics of 1617 cases is shown in Table 1. The onset symptoms were evenly distributed 
(the district-specific figures are not shown), as were the total F/M ratio (2.2), median age at onset (32.0) and 
age at diagnosis (37.0 years). The median diagnostic delay decreased from 4.0 years to 2.0 years (Chi-
square test p<0.001) during the study periods. Paraclinical studies in 10-year periods are shown in Table 2. 
The CSF (including either the IgG index, immunoelectrophoresis, or both) was performed in 89-92% of the 
cases. The decreasing use of evoked potentials (27% to 19%) and the increasing use of MRI (36% to 98%) 
was observed during the follow-up evaluation. 
 
The second scan, which was used to study dissemination in time and space in 65% of the cases, was 
performed during the next 18 months after the first scan in 58% of the cases, 94% of which were positive 
for MS (Figure 2). The delay to the first MRI from the date of onset of symptoms was significantly 
decreased during the follow-up evaluation. From January 1, 1981 to December 31, 2010, the age-adjusted 
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incidence was 6.7 × 105 (95% CI: 6.2-7.2) in Pirkanmaa, 12.5 × 105 (95% CI: 11.5-13.5) in Seinäjoki and 8.3 
× 105 (95% CI: 7.4-9.2) in Vaasa. The SIR was 1.9 × 105 (95% CI: 1.7-2.0) in Seinäjoki, 1.2 × 105 (95% CI: 
1.1-1.4) in Vaasa, compared to Pirkanmaa (SIR 1.0 × 105). 
 
The incidence for 10-year periods (1981-1990, 1991-2000, 2001-2010) is shown in Table 3. A steady 
increase in Pirkanmaa (from 5.1 to 8.2) and a two-fold increase in both Seinäjoki (from 7.1 to 14.7) and 
Vaasa (from 5.7 to 11.7) were observed. The female incidence was significantly higher in all age groups 
and in all districts. The male incidence decreased during the last decade in Vaasa and Seinäjoki. The F/M 
ratios remained stable in Pirkanmaa (2.5, 2.1, 2.2) and increased 1.3–fold (1.8, 1.9, 2.3) in Seinäjoki and 
1.6-fold (1.8, 2.1, 2.8) in Vaasa. 
 
The F/M ratios in the 10-year age groups according to district are shown in Figure 3. The highest F/M ratio 
of to 3.5 was observed in the 10-19-year age group. In Pirkanmaa, the ratio subsequently remained stable, 
whereas peaks were observed in Seinäjoki (age group: 30-49-years) and Vaasa (age group: 30-39-years). 
 
Female risk values in Seinäjoki (1.8, 95% CI: 1.7-2.0) and Vaasa (1.5, 95% CI: 1.3-1.7) were similar, and 
the age-specific incidence peaked at 30-39 years (Figure 4). Male risk in Seinäjoki was 2-fold compared to 
Pirkanmaa (SIR 2.00, 95% CI: 1.7-2.3) and the incidence was high in the large age group (20-59-year-olds). 
In Vaasa, male risk (1.4, 95% CI: 1.2-1.7) peaked in the older age groups. 
 
DISCUSSION 
 
Regional differences in MS epidemiology were among the earliest observations made in Finland [8,9,10]. 
Earlier observations on high-risk MS in Seinäjoki have also been confirmed here, because the 30-year 
incidence rate of 12.5/105 person-years in 2010 was among the highest reported [8,10]. The incidence was 
8.3 and 6.7 in Vaasa and Pirkanmaa, respectively. However, the regional MS risk in Seinäjoki remains 
nearly two-fold (SIR 1.9) compared to Vaasa (1.2) and Pirkanmaa (1.0) in Finland. The southern and 
urbanized Uusimaa district, which is located in the capital city Helsinki, and Pirkanmaa (formerly Häme) 
are regarded as regions with similar and standard MS risk in Finland [8,10]. This perception holds true, 
because an incidence of 5.1 in Uusimaa was reported in 1993 [10], which was similar to the rate of 5.1 in 
Pirkanmaa in 1981-1990. 
 
Consistent with these findings, contemporary studies performed in Ireland and Wales [2,14] revealed an 
approximately 1.5–fold increase in the F/M ratio, observed also in this study in districts of Seinäjoki and 
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Vaasa from 1981-2010. Ratios of 2.3 in Seinäjoki and 2.8 in Vaasa in 2010 exceeded the corresponding 
ratios of 1.6 and 2.2 in an earlier study from 1979-1993[10]. However, the ratio in Pirkanmaa remained 
stable, which was consistent with other previous studies [15,16]. 
 
MS affects women during their most active years of life. In this study, we showed the highest F/M ratio of 
3.5 in the 10-19-year age group, where the total incidence remains low. The female preponderance 
remained high in the 20-59-year age group. Thus, the high F/M ratio in the youngest age group may 
indicate the presence of risk factors affecting this female subpopulation, independent of a geographically 
associated risk. The local risk of multiple sclerosis in Seinäjoki may be explained by genetic factors because 
HLA characterization has demonstrated increased frequencies for B7, B12, and DR2 among both patients 
and their healthy relatives [17]. The patients’ families were subsequently examined for the myelin basic 
protein (MBP) gene on chromosome 18, which is a candidate gene involved in multiple sclerosis. Genetic 
linkage and association analyses suggested that a genetic predisposition to multiple sclerosis was closely 
linked to the MBP gene in this population [18]. Despite this finding, the genetic background was similar in 
rural areas of partially Swedish-speaking Vaasa, Finnish-speaking Seinäjoki and the more urbanized 
Pirkanmaa [19, 20,21]. 
 
Risk among males was increased in Seinäjoki despite the presence of a declining male incidence. The SIR 
for males remained 2-fold (2.0, 95% CI: 1.7-2.3), with an SIR of 2.8 (95% CI: 2.3–3.5) reported in an 
earlier study in 1979-93 [10]. Although the SIRs for males in both Seinäjoki and Vaasa (1.4) were higher 
compared to Pirkanmaa, they did not differ from the female ratios. Given that the populations examined 
were genetically homogeneous and stable and that the genetic changes in these populations were slow, the 
genderspecific incidence trends observed in this study indicated that environmental factors affecting the 
increased male MS risk in high-risk districts were less powerful than factors affecting the increasing female 
preponderance in the 1990´s. According to this observation, the factors affecting males and females may be 
different in general, and some of these factors may act temporally and locally. 
 
The common awareness of MS and the availability of MRI from 1993 in all districts, together with revised 
criteria and justified early DMT start in RRMS have also precipitated MS diagnosis in Finland [22,23]. The 
diagnostic evaluation performed in this study was on the basis of the International and National Current 
Care Guidelines [24,25,26]. Due to a highly centralized health care system, we were able to obtain full 
coverage of the MS patients in this population-based study. The diagnosis-based incidence was used to 
avoid proportional incidence and underestimated risk, in addition to problems with recognition and the 
definition of the historical and often arbitrary onset symptoms in long-term follow-up evaluations [10]. We 
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included definite MS cases to consolidate regional and temporal comparisons. Active CSF sampling in 
Finland promoted the application of Poser criteria [12], in which a positive finding was essential. CSF was 
considered fundamental in differential diagnostics for MS [27]. Because purely clinical diagnoses were 
nearly nonexistent in 2001-2010, diagnostic specificity may be considered high in this cohort. However, the 
number of cases was fairly low, and the population in central parts of the country was younger compared to 
Seinäjoki and Vaasa, which was among the factors that may confound a regional and temporal comparison 
of incidence [11]. Thus, because small numbers were generally present in the age- and gender-specific 
strata, we decided to use indirect standardization in the risk calculations performed in this study [13]. 
 
We observed a significant decrease in the diagnostic delay, which was consistent with rapid MR imaging 
after the first symptoms in 2001-2010 in each district. Despite this finding, the incidence during the last 10 
ten-year period in both Vaasa and Seinäjoki showed a stabilization after a two-fold increase in 1981-2000. 
In 1981-2010, the population at risk in the 10-39-year age groups decreased to 11% and 26% in Vaasa and 
Seinäjoki, respectively. The number of MS cases in 2001-2010 decreased by 21% in both Seinäjoki (a 
decrease from 122 to 96 patients) and Vaasa (from 80 to 63 patients), which was observed in males and was 
mainly due to the recent stabilization and observed incidence decline. In Pirkanmaa, the population only 
decreased by 3% and the number of new MS cases increased by 23% (from 130 to 168 patients), which was 
accompanied by a steadily increasing trend. Despite these recent differences in population structure, the 
current sources of livelihood were similar in the districts, including those of the Swedish-speaking 
population (22%) in the Vaasa district, which may indicate why the environmental risk factors may be 
connected to changes and differences in lifestyle. 
 
In conclusion, Seinäjoki and Vaasa represented high MS risk areas, where risk was observed to be high 
among females, peaking in the youngest age group, and among males in a large age group. However, high 
risk in general reflects both genetic and environmental effects. These effects may also be shared among 
other autoimmune diseases, such as type 1 diabetes mellitus, which predominantly affects males. The 
incidence of type 1 diabetes mellitus closely follows MS, both geographically and temporally, in Finland 
[28]. Thus, population-based case control studies are required to further characterize these factor effects, 
which may include a role for Vitamin D, several lifestyle factors (including smoking, obesity and hormone 
replacement therapy) and later childbirth among females. 
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Table 1. Characteristics of MS cases in Pirkanmaa, Seinäjoki 
and Vaasa during the period 1981-2010 
 
Number of cases, n (%) 
Total      1617 
Male      512 (32) 
Female     1105 (68) 
F/M      2.2 
 
Diagnosis using Poser, n (%) 
CDMS     60 (4) 
CDMS + paraclinical   1223 (75) 
LSDMS     75 (5) 
LSDMS + paraclinical   259 (16) 
 
Age, years 
At onset, median    32 
At the time of diagnosis, median  37 
 
Diagnostic delay, years 
Mean      4.6 
Median     2.0 
 
First symptoms by anatomic level, % 
Brainstem/cerebellum   25 
Visual tract     22 
Sensory     22 
Medullary     19 
Pyramidal tract above medulla  5 
Other/UN     4 
Multiple     3 
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Table 2. Case ascertainment in MS diagnostics during three study periods 1981-1990,1991-2000,2001-
2010 in Pirkanmaa, Seinäjoki and Vaasa. 
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Table 3. Incidence of MS during the three decades examined in Pirkanmaa, Seinäjoki and Vaasa. 
Period  1981-1990  1991-2000  2001-2010 
             
District  Inc/10
5
 95% CI N  Inc/10
5
 95% CI N  Inc/10
5
 95% CI N 
             
Pirkanmaa             
Men  3.0 (2.2 - 3.8) 48  4.1 (3.1 - 5.1) 70  5.1 (4.1 - 6.1) 92 
Women  7.1 (5.8 - 8.4) 119  8.8 (7.4 - 10.2) 149  11.5 (9.9 - 13.1) 206 
Total  5.1 (4.3 - 5.9) 167  6.5 (5.4 - 7.4) 219  8.2 (7.3 - 9.1) 298 
             
Seinäjoki             
Men  5.0 (3.5 - 6.5) 44  10.5 (8.2 - 12.8) 83  8.6 (6.5 - 10.7) 66 
Women  9.2 (7.2 - 11.2) 79  20.3 (17.1 - 23.5) 154  21.0 (17.7 - 24.3) 152 
Total  7.1 (5.8 - 8.4) 123  15.3 (13.4 - 17.2) 237  14.7 (12.7 - 16.7) 218 
             
Vaasa             
Men  4.1 (2.5 - 5.7) 25  7.4 (6.3 - 8.5) 46  6.0 (4.6 - 7.4) 38 
Women  7.4 (5.2 - 9.6) 45  16.0 (14.4 - 17.6) 96  17.6 (14.2 - 21.0) 105 
Total  5.7 (4.4 - 7.1) 70  11.7 (10.7 - 12.7) 142  11.7 (9.8 - 13.6) 143 
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Figure 1. Map of Finland. Finland lies in Scandinavia, North Europe between latitudes 60-70°N. Gulf 
of Bothnia in northern most part of Baltic Sea limits the west coast. The total population was 5.4 
million in 2010. University District of Tampere is demarcated, and location of central hospitals and 
hospital districts in Pirkanmaa (oblique lines), Seinäjoki (dots) and Vaasa (dark grey) are pointed in the 
map. 
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Figure 2. Percentage of performed MRI scans by time from disease onset among MS cases diagnosed 
between 1981 and 2010. 
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Figure 3. F/M -ratio by total number in 10-year age-groups among cases diagnosed during 1981-2010 
in hospital districts of Pirkanmaa, Seinäjoki and Vaasa. There were no men in the 10-19 –group in 
Seinäjoki. 
 
 
 
 
 
 
 
Pirkanmaa    22             189           221           178            64             10 
        Vaasa    9                76            115           101            47              7 
   Seinäjoki    10             121           179           174            79             15 
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Figure 4. Incidence of MS in the 10-year age groups in Pirkanmaa, Seinäjoki and Vaasa hospital 
districts during the period 1981-2010. 
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